UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 10, 2018
 
AIT Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
 
000-55759
 
47-3812456
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
500 Mamaroneck Avenue, Suite 320
Harrison, NY 10528
(Address of Principal Executive Office)
 
Registrant’s telephone number, including area code:  (516) 665-8200
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter ) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter ).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
On May 10, 2018, the Board of Directors of AIT Therapeutics, Inc., a Delaware corporation (the “Company”), approved the change in the Company’s fiscal year end from December 31 to March 31, beginning on March 31, 2018.  Under the applicable rules of the Securities and Exchange Commission, the Company intends to file a transition report on Form 10-KT that will cover the three-month transition period from January 1, 2018 to March 31, 2018 on or prior to August 8, 2018.
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
AIT THERAPEUTICS, INC.
   
Date: May 10, 2018
 
 
By:  /s/ Steven Lisi
Steven Lisi
Chief Executive Officer